Erbitux Opportunity In Japan Has Been Overlooked By Investors
This article was originally published in PharmAsia News
Executive Summary
ImClone said July 16 that its oncologic Erbitux (cetuximab) has been approved in Japan for treatment of advanced colon cancer. Under an existing deal, Merck KGaA will receive 50 percent of profits from sales in Japan, and ImClone and Bristol-Myers Squibb will receive 25 percent each. An application for Erbitux in earlier-stage colon cancer is pending with Japanese regulators. Several analysts say that the Japanese market is an opportunity for Erbitux that has been overlooked by investors. (Click here for more